Cancer Cells in all EMT States Lack Rigidity Sensing Depletion of Different Tumor Suppressors Causes Loss of Rigidity Sensing in Cancer Cells

Chloe Simpson, Vignesh Sundararajan, Tuan Zea Tan, Ruby Yun‐Ju Huang, Michael P. SheetzbioRxiv 2022 · DOI

TL;DR

This study reveals that a broad range of ovarian cancer cell lines, regardless of their epithelial-to-mesenchymal transition (EMT) state, have lost the ability to sense substrate stiffness. This loss of rigidity sensing, often due to the absence of key mechanosensitive proteins like TPM2.1, appears to be a fundamental characteristic of cancer cells, enabling their growth on soft surfaces and contributing to the transformed phenotype.

What Problem Does This Paper Address?

Cancer cells exhibit remarkable adaptability, growing in diverse environments and often resisting targeted therapies. While the epithelial-to-mesenchymal transition (EMT) is known to influence cancer cell behavior and metastasis, the underlying mechanisms that allow cancer cells to thrive in various physical conditions, particularly on soft substrates, remain incompletely understood. Previous research suggested that normal cells require rigid surfaces to grow, while transformed cells can grow on soft surfaces. This paper investigates whether this ability to grow on soft surfaces, a hallmark of transformation, is a universal trait among cancer cells and if it's linked to the loss of a specific cellular mechanism: rigidity sensing. The authors hypothesize that the loss of rigidity sensing is a common, perhaps necessary, step in cancer cell transformation.

Methods

The researchers employed a multi-pronged approach to investigate rigidity sensing in cancer cells:

  • Western Blotting: This technique was used to quantify the protein levels of key mechanosensitive proteins (TPM2.1, TPM3, FLNA, PTPN12, and Myosin IIA) across a panel of 36 ovarian cancer cell lines. This allowed them to identify which proteins were present or absent in different cell lines.
  • Micropillar Assays: This is a core technique for measuring rigidity sensing. Cells were plated on arrays of tiny, flexible pillars. As cells spread and exert forces, they cause the pillars to deflect. By analyzing the correlated deflections of adjacent pillars, researchers can determine if the cell is actively sensing and responding to the substrate's stiffness.
  • Actin Alignment (Nematic Order Parameter): The alignment of actin filaments within a cell is known to change in response to substrate stiffness. The researchers stained for actin and quantified its alignment using a nematic order parameter to assess if cells were responding to different stiffnesses.
  • Cell Culture: A diverse panel of ovarian cancer cell lines, representing a spectrum of EMT states, along with control cell lines (a normal human foreskin fibroblast and a transformed ovarian epithelial cell line), were cultured for these experiments.

Datasets

The study utilized a panel of 36 ovarian cancer cell lines, previously compiled to represent a full spectrum of epithelial to mesenchymal phenotypes. These cell lines originated from various ovarian cancer subtypes, diseases, and stages, including both primary tumors and metastatic samples. Additionally, a normal human foreskin fibroblast cell line (BJ-5ta) and a transformed ovarian epithelial cell line (IOSE523) were used as controls.

Key Insights and Ideas

  • Universal Loss of Rigidity Sensing: The most striking finding is that all tested ovarian cancer cell lines, regardless of their EMT status or origin, lacked the ability to sense substrate stiffness. This suggests that losing rigidity sensing is a fundamental characteristic of cancer cells, not just a feature of specific subtypes or stages.
  • TPM2.1 as a Key Player: A significant proportion of cancer cell lines were missing TPM2.1, a crucial protein for rigidity sensing. This points to TPM2.1 as a potential tumor suppressor whose loss contributes to the transformed phenotype.
  • TPM3 as an Oncogene Candidate: Conversely, TPM3 was consistently highly expressed across all cell lines, suggesting it might play an oncogenic role or be a marker of the transformed state.
  • Multiple Pathways to Rigidity Loss: The study highlights that cancer cells can lose rigidity sensing through various means, including the absence of TPM2.1, PTPN12, FLNA, or Myosin IIA, or even through unknown mechanisms. This explains the diversity of molecular alterations seen in cancer.
  • Rigidity Sensing Loss Precedes EMT: The data suggests that the loss of rigidity sensing is an early event in metastatic progression, occurring before the epithelial-to-mesenchymal transition (EMT). This challenges the notion that EMT is the sole driver of these changes.
  • Therapeutic Implications: The universal loss of rigidity sensing in cancer cells suggests that targeting this pathway could be a broad-spectrum therapeutic strategy, potentially inhibiting the growth of a wide range of tumors.

Key Results

  • 18 out of 36 ovarian cancer cell lines showed no expression of TPM2.1.
  • All 36 cell lines expressed high levels of TPM3.
  • Seven cell lines had very low or no expression of PTPN12.
  • One cell line lacked FLNA, and another lacked Myosin IIA.
  • In micropillar assays, all tested tumor cell lines exhibited significantly lower rigidity sensing activity compared to the normal human foreskin fibroblast control.
  • Actin alignment analysis showed that ovarian cancer cell lines did not exhibit differential actin organization in response to soft versus rigid substrates, unlike the control fibroblast cells.

Limitations and Future Work

  • Unknown Mechanisms: While the study identifies the loss of rigidity sensing as a common trait, the precise mechanisms by which some cell lines lose this ability, when all key proteins are present, remain unknown.
  • Broader Cancer Types: The study focused on ovarian cancer cell lines. Future work could explore whether this loss of rigidity sensing is a universal characteristic across many other cancer types.
  • Therapeutic Validation: The paper proposes that targeting rigidity sensing could be a therapeutic strategy. Further research is needed to validate this hypothesis and develop specific interventions.
  • Role of TPM3: The consistent high expression of TPM3 warrants further investigation into its specific role in promoting cancer cell growth and transformation.

Summary updated

Abstract

Abstract Cancer cells have many different behaviors from epithelial to mesenchymal forms. We report here that 36 distinct tumor cell lines regardless of EMT form or other features lack the ability to sense rigidity and will grow on soft surfaces. In the majority of lines, cells were missing at least one protein needed for rigidity sensing (primarily tropomyosin2.1 (Tpm2.1) but also PTPN12, FilaminA (FLNA), and myosinIIA) while all had high levels of Tpm3. In the few cases where the major rigidity sensing components were present, those tumor cells were not able to sense rigidity. Thus, we suggest that tumor cells can lose the ability to sense rigidity by many different means and that the loss of rigidity sensing is sufficient to cause the transformed phenotype that enables targeted treatments.
BibTeX
@misc{simpson2022cancer,
  author = {Chloe Simpson and Vignesh Sundararajan and Tuan Zea Tan and Ruby Yun‐Ju Huang and Michael P. Sheetz},
  title = {{Cancer Cells in all EMT States Lack Rigidity Sensing Depletion of Different Tumor Suppressors Causes Loss of Rigidity Sensing in Cancer Cells}},
  year = {2022},
  doi = {10.1101/2022.06.06.495045},
  howpublished = {bioRxiv},
}
Figure